HS-20093, a B7-H3-targeted ADC independently developed in China, demonstrated robust clinical efficacy in a phase I trial involving patients with ES-SCLC previously treated with platinum-based chemotherapy with or without ICIs. The gene discussed is CD276; the disease is small cell lung carcinoma.